Archives

  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br In summary patients treated at Moffitt were

    2020-07-27


    In summary, patients treated at Moffitt were more often treated with systemic treatment and had a higher survival rate. Differences in survival were largely explained by differences in treatment and less pro-nounced in comparison with academic hospitals in the Netherlands. Further detailed analyses of selection criteria for systemic treatment and assessment of quality of life could lead to tailored treatment and im-proved outcomes in older patients with pancreatic cancer.
    Authors Contributions
    Study concepts: EMdL, EB, ME- Study design: EMdL, EB, ME- Data acqui-
    Quality control of data and algorithms: EMdL, EB, LGMvdG, ME- Data
    analysis and interpretation: EMdL, EB, ME- Statistical analysis: EMdL,
    EB, − Manuscript preparation: EMdL, EB, LGMvdG, KME, CJHvdV, LB,
    BAB, ME- Manuscript editing: EMdL, EB, LGMvdG, KME, CJHvdV, LB,
    BAB, ME- Manuscript review: EMdL, EB, LGMvdG, KME, CJHvdV, LB, BAB, ME. No conflict of interest to report for all authors. 
    Acknowledgements
    The authors thank the registration teams of the Comprehensive Cancer Centre Netherlands for the collection of data for the Netherlands Cancer Registry and the scientific staff of the Comprehensive Cancer Centre Netherlands. The authors would also like to thank the Total Cancer Care and the Moffitt Cancer Registry for provision of data used in the current study. This work was supported by a grant from the Dutch Cancer Society.
    Appendix A. Supplementary Data
    Supplementary data to this LY 379268 article can be found online at https://doi.
    References
    [1] Sehgal R, Alsharedi M, Larck C, Edwards P, Gress T. Pancreatic cancer survival in elderly patients treated with chemotherapy. Pancreas 2014 Mar;43(2):306–10. [2] Brachet D, Lermite E, Vychnevskaia-Bressollette K, Mucci S, Hamy A, Arnaud JP. Should pancreaticoduodenectomy be performed in the elderly? Hepatogastroenterology 2012 Jan;59(113):266–71.
    [13] Turrini O, Paye F, Bachellier P, Sauvanet A, Sa CA, Le Treut YP, et al. Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term re-sults: a study of the French Surgical Association. Eur J Surg Oncol 2013 Feb;39(2): 171–8.
    [14] van der Geest LG, Besselink MG, van Gestel YR, Busch OR, de Hingh IH, de Jong KP, et al. Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol 2016;55(3):278–85. [15] Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2011 Aug 1;80(5):1391–7.
    [16] Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and che-motherapy following curative resection. Arch Surg 1985 Aug;120(8):899–903. [17] Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant che-moradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001 Nov 10;358(9293):1576–85.
    [18] Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A random-ized trial of chemoradiotherapy and chemotherapy after resection of pancreatic can-cer. N Engl J Med 2004 Mar 18;350(12):1200–10. [19] Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemo-therapy with gemcitabine vs observation in patients undergoing curative-intent re-section of pancreatic cancer: a randomized controlled trial. JAMA 2007 Jan 17;297
    [20] Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010 Sep 8;304 (10):1073–81. [21] Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013 Oct 9; 310(14):1473–81.
    [22] Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Com-parison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in
    [24] Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, et al. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carci-noma. J Gastroenterol 2010 Nov;45(11):1146–54. [25] Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002 Dec;29(6 Suppl 20):9–16.
    [28] Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancre-atic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 May 20;25(15):1960–6.